{
    "organizations": [],
    "uuid": "b9b8979cfcf295cc6c082df9f3597946050266b3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-tetraphase-posts-top-line-results/brief-tetraphase-posts-top-line-results-from-ignite3-phase-3-clinical-trial-of-eravacycline-in-cuti-idUSASB0C5HK",
    "ord_in_thread": 0,
    "title": "BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 13, 2018 / 9:13 PM / Updated 9 minutes ago BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI Reuters Staff 1 Min Read Feb 13 (Reuters) - Tetraphase Pharmaceuticals Inc: * TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI) * TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE DID NOT ACHIEVE CO-PRIMARY ENDPOINTS IN CUTI TRIAL​ * TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE WAS WELL TOLERATED IN IGNITE3​ * TETRAPHASE - ‍CONTINUES TO PREPARE FOR COMMERCIALIZATION OF ERAVACYCLINE AS A TREATMENT FOR CIAI IN U.S. AND EUROPE, ASSUMING REGULATORY APPROVAL​ * TETRAPHASE PHARMACEUTICALS INC - ‍CONTINUE TO MOVE FORWARD WITH OUR REGISTRATION STRATEGY FOR ERAVACYCLINE IN COMPLICATED INTRA-ABDOMINAL INFECTIONS​ * TETRAPHASE PHARMACEUTICALS- STUDY FAILED TO MEET CO-PRIMARY EFFICACY ENDPOINTS OF RESPONDER RATE IN MICRO-ITT POPULATION AT EOI TREATMENT VISIT, TOC VISIT Source text for Eikon: Further company coverage:",
    "published": "2018-02-13T23:12:00.000+02:00",
    "crawled": "2018-02-13T23:29:30.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "post",
        "result",
        "ignite3",
        "phase",
        "clinical",
        "trial",
        "eravacycline",
        "cuti",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "tetraphase",
        "announces",
        "result",
        "ignite3",
        "phase",
        "clinical",
        "trial",
        "eravacycline",
        "complicated",
        "urinary",
        "tract",
        "infection",
        "cuti",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "achieve",
        "endpoint",
        "cuti",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "well",
        "tolerated",
        "tetraphase",
        "prepare",
        "commercialization",
        "eravacycline",
        "treatment",
        "ciai",
        "europe",
        "assuming",
        "regulatory",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "move",
        "forward",
        "registration",
        "strategy",
        "eravacycline",
        "complicated",
        "tetraphase",
        "study",
        "failed",
        "meet",
        "efficacy",
        "endpoint",
        "responder",
        "rate",
        "population",
        "eoi",
        "treatment",
        "visit",
        "toc",
        "visit",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}